EUVIMEDEUVIMED entdecken
Validierungsstudie

A Method for Validating PET and SPECT Cameras for Quantitative Clinical Imaging Trials Using Novel Radionuclides

Dale L Bailey, Kathy P Willowson, Graeme O'Keefe, Steven Goodman, Shaun Patford, George McGill, David A Pattison, Andrew M Scott, I-FIRST investigators and ARTnet

Journal of Nuclear Medicine · 2025

DOI: 10.2967/jnumed.124.268578 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Journal of Nuclear Medicine, 2025. Verfasst von Dale L Bailey und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia; dale.bailey@sydney.edu.au. Hauptthemen laut MEDLINE: Tomography, Emission-Computed, Single-Photon, Positron-Emission Tomography, Clinical Trials as Topic, Gamma Cameras. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Our aim is to report methodology that has been developed to calibrate and verify PET and SPECT quantitative image accuracy and quality assurance for use with nonstandard radionuclides, especially with longer half-lives, in clinical imaging trials.

Methods

Procedures have been developed for quantitative PET and SPECT image calibration for use in clinical trials. The protocol uses a 3-step approach: check quantitative accuracy with a previously calibrated radionuclide in a simple geometry, check the novel trial radionuclide in the same geometry, and check the novel radionuclide in a more challenging, complex geometry (the National Electrical Manufacturers Association [NEMA] NU-2 International Electrotechnical Commission [IEC] image-quality phantom). The radionuclides used in the trial as an example are 124I (PET) and 131I (SPECT). In both cases, whole-body tomographic SPECT and PET imaging with accompanying low-dose CT are required. PET accuracy is based on calibrating the dose calibrator to produce quantitative images for radionuclides other than 18F, with all images reconstructed on each individual site’s PET systems. For SPECT, an independent sensitivity measurement is made and then used to calibrate the SPECT images reconstructed at the core laboratory. After calibration, the final testing for both PET and SPECT uses the NEMA NU-2 IEC image-quality phantom to derive several metrics including quantitative accuracy based on an average SUV (SUVavg).

Results

Using the method described, 7 sites in Australia have been qualified for 10 PET/CT scanners using 124I imaging and 8 SPECT/CT systems for 131I. One PET/CT system was found to give a result outside the specification of an SUVavg of 1.0 ± 0.05. All SPECT/CT systems gave an SUVavg accurate to within ±10% (SUVmean, 1.0 ± 0.1) of the true value for reconstructed radioactivity concentration in Bq/cm3.

Conclusion

A general methodology has been developed to calibrate and validate PET and SPECT systems for quantitative imaging in clinical trials. The preparation of the test objects and the procedures is relatively simple and can generally be implemented by the staff at the site of the imaging center with the equipment supplied by the clinical trials organization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tomography, Emission-Computed, Single-PhotonPositron-Emission TomographyClinical Trials as TopicGamma CamerasHumansPhantoms, ImagingCalibrationReproducibility of ResultsIodine Radioisotopes

Stichwörter der Autor:innen

PETSPECTclinical trialssite validation

Substanzen

Iodine Radioisotopes

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia; dale.bailey@sydney.edu.au.
  • Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
  • Department of Nuclear Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia.
  • Institute of Medical Physics, Faculty of Science, University of Sydney, Sydney, New South Wales, Australia.
  • Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Victoria, Australia.
  • Department of Nuclear Medicine, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.

Zitieren

APA

Bailey, D. L., Willowson, K. P., O'Keefe, G., Goodman, S., Patford, S., McGill, G., Pattison, D. A., Scott, A. M., & I-FIRST investigators and ARTnet (2025). A Method for Validating PET and SPECT Cameras for Quantitative Clinical Imaging Trials Using Novel Radionuclides. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.124.268578

Vancouver

Bailey DL, Willowson KP, O'Keefe G, Goodman S, Patford S, McGill G, et al. A Method for Validating PET and SPECT Cameras for Quantitative Clinical Imaging Trials Using Novel Radionuclides. Journal of Nuclear Medicine. 2025. doi:10.2967/jnumed.124.268578

BibTeX
@article{Bailey2025,
  author = {Bailey, Dale L and Willowson, Kathy P and O'Keefe, Graeme and Goodman, Steven and Patford, Shaun and McGill, George and Pattison, David A and Scott, Andrew M and I-FIRST investigators and ARTnet, I-FIRST investigators and ARTnet},
  title = {A Method for Validating PET and SPECT Cameras for Quantitative Clinical Imaging Trials Using Novel Radionuclides},
  journal = {Journal of Nuclear Medicine},
  year = {2025},
  doi = {10.2967/jnumed.124.268578}
}
Kostenlos starten →